Crucell 2010 Annual General Meeting of Shareholders 2009 Financial Statements Adopted; All Resolutions Approved
(Thomson Reuters ONE) -
Leiden, The Netherlands (June 4, 2010) - Dutch biopharmaceutical company Crucell
N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that the
Annual General Meeting of Shareholders (AGM) held today in Leiden adopted the
2009 financial statements. In addition, the AGM reappointed Mr. J.P. Oosterveld
as member of the Supervisory Board; Mr. W. Burns, Mr. J. Shannon and Mr. G.
Siber were appointed as new members of the Supervisory Board.
The shareholders of Crucell were represented in person, by proxy voting, or by
voting instruction, representing a total of 36,2% of the total issued share
capital entitled to vote.
The shareholders approved the appointments of Mr. William Burns, Mr. James
Shannon and Mr. George Siber as members of the Supervisory Board. The
appointments are for a term of four years, until 2014. The Chairman of the
Supervisory Board, Mr. Jan Pieter Oosterveld was reappointed for a term of four
years by Crucell's shareholders.
Furthermore the AGM approved the 2009 financial statements and all other
resolutions.
At the meeting, presided by Jan Oosterveld, Chairman of the Supervisory Board,
Ronald Brus, CEO of Crucell and Leon Kruimer, CFO discussed the company's 2009
results, reiterated the outlook for 2010 [1], and presented their views on the
business and strategy of the company to shareholders. The slides of the
presentation given at the AGM are available on the company's website
www.crucell.com
Forward-looking statements
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the US Securities and Exchange Commission
on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares
its financial statements under International Financial Reporting Standards
(IFRS).
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. In 2009 alone, Crucell distributed more than 115 million
vaccine doses in more than 100 countries around the world, with the fast
majority of doses (97%) going to developing countries. Crucell is one of the
major suppliers of vaccines to UNICEF and the developing world. Crucell was the
first manufacturer to launch a fully-liquid pentavalent vaccine called
Quinvaxem(®). Quinvaxem(®) protects against five important childhood diseases
and over 130 million doses have been sold since its launch in 2006 in more than
50 GAVI countries. Through Quinvaxem(®) and its innovation, Crucell has become a
major partner in protecting children in developing countries. Crucell's core
portfolio also includes a vaccine against hepatitis B and a virosome-adjuvanted
vaccine against influenza. Crucell also markets travel vaccines, such as an oral
anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free
hepatitis A vaccine on the market. The Company has a broad development pipeline,
with several product candidates based on its unique PER.C6(®) production
technology. The Company licenses its PER.C6(®) technology and other technologies
to the biopharmaceutical industry. Important partners and licensees include
Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and
Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden, Switzerland, UK
and the USA. The Company employs over 1200 people. For more information, please
visit www.crucell.com
[1] Use continued strong operating cash flow to accelerate product development.
R&D spending to increase by over one-third. Maintain a healthy operating profit.
Revenues and other operating income broadly in line with 2009. (Guidance
currency = EUR/USD rate of 1.41).
For further information please contact:
Crucell N.V.
Oya Yavuz
Vice President
Corporate Communications & Investor Relations
Tel. +31-(0)71-519 7064
www.crucell.com
[HUG#1421808]
PDF file: http://hugin.info/132631/R/1421808/371009.pdf
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Terra Ventures update regarding Terrex Energy spin-out transaction.
Datum: 04.06.2010 - 16:53 Uhr
Sprache: Deutsch
News-ID 21990
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell 2010 Annual General Meeting of Shareholders 2009 Financial Statements Adopted; All Resolutions Approved"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
